Entrada Therapeutics Inc. held its 2025 Annual Meeting of Stockholders on June 11, 2025, in a virtual-only format. During the meeting, stockholders voted on two main proposals. The first proposal was the election of three Class I director nominees to the Board of Directors. Dipal Doshi, Kush M. Parmar, M.D., Ph.D., and Mary Thistle were all elected as directors. The second proposal was the ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, which was also approved.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.